Next-generation Sequencing Market Size, Trends And Forecast To 2032
According to Nova one advisor, the global Next-generation Sequencing Market Size was valued at USD 7.45 billion in 2022 and is predicted to be worth USD 28.19 billion by 2032, with a CAGR of 17.2% from 2023 to 2032.
Key Takeaways:
Next-generation Sequencing (NGS) is a parallel processing technique that can establish the sequence of nucleotides in a whole genome with scalability, ultra-high capacity, and fast speed. Furthermore, in the healthcare industry, NGS is gradually being incorporated into medical laboratory research, screening, and disease diagnoses. In personalized medicine, it has been frequently utilized to accelerate the drug research process.
Different potential sequencing methods such as RNA sequencing, whole-genome sequencing, and whole-exome and targeted sequencing amongst others are prominently used by researchers to get comprehensive sample analysis. When compared to the traditional Sanger sequencing technology, NGS is less expensive and provides higher throughput for DNA sequencing. The growing automation in the pre-sequencing protocols, post-sequencing protocols, and data analysis is also projected to have a positive impact on the NGS market. The utilization of novel platforms for the development of personalized medicine by medical analysis at a genetic level is also a significant factor, which is expected to enhance demand for NGS over the forecast period.
Besides, there are other significant growth trends that are being witnessed in the sequencing industry, such as the development of personalized medicine and companion diagnostics, growing advancements in cloud computing, and data integration. Furthermore, the easy availability of genomic and proteomic data has poised this market to exhibit potentially high-value avenues and opportunities for growth over the forecast period. The market growth is also being fueled by an increase in the global prevalence of cancer and the availability of sophisticated healthcare facilities. As per GLOBOCAN 2020, there have been 1,92,92,789 new cancer cases in 2020, with the number expected to rise to 2,88,87,940 by 2040. Such a substantial rise in the number of cancer cases is estimated to leverage cancer research which will eventually accelerate the NGS market growth.
The NGS diagnostic techniques have the potential to determine a virus's genomic sequence and aid scientists in their understanding of mutations. Furthermore, throughout the COVID-19 epidemic, governments across the globe have been collaborating with the corporate sector to introduce NGS technology to the market as a viable diagnostic tool. The US Food and Drug Administration granted Illumina Inc. a case of emergency use permit for the first COVID-19 diagnostic using the next-generation sequence technique in June 2020. The Illumina COVIDSeq Test for qualitative identification of SARS-CoV-2 RNA has been approved by the FDA. As a result, the usage of next-generation sequencing (NGS) technologies is projected to increase during the pandemic.
Report Scope of the Next-generation Sequencing Market
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 8.55 Billion |
|
Market Size by 2032 |
USD 28.19 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 17.2% |
|
Base Year |
2022 |
|
Forecast Period |
2023 to 2032 |
|
Segments Covered |
Technology, product, application, workflow, end-use and Geography |
Application Insights
The oncology segment dominated the market and accounted for the highest market share of 29.5% in 2022. A gradually growing prevalence of cancer warrants the use of the latest technology to enable oncologists better understand the mechanics of cancer and tumor cells and the application of NGS for DNA and RNA sequencing, epigenetics, and analyzing chromosomal abnormalities account for over three-fourths of the global sequencing data are factors responsible for high market share. Companies like Myriad, through its myRisk product, offer genetic testing to identify people who may be at higher risk of developing certain cancers in the future. In January 2021, Merus N.V.; a clinical-stage immuno-oncology company; collaborated with National Cancer Center, Japan, and Erasmus University Medical Center, Netherlands to evaluate its HER2/3-targeting bispecific antibody in solid tumors.
Furthermore, the continuous introduction of new products by the key players is driving growth in the consumer genomics segment. The presence of companies such as 23andMe that are involved in the provision of the “Personal Genome Service” can be attributed to growth in the coming years. Moreover, Ancestry.com, Color Genomics, Cloud Health (which purchased a HiSeq X Ten), National Geographic, and several Japanese consumer companies, as well as a nascent consumer business, Helix, which was launched by Illumina are expected to impact revenue generation in this segment. Rapid proliferation in genealogy, paternity testing, and personal health awareness is expected to drive the growth in consumer genomics, as an application of NGS.
Technology Insights
The targeted sequencing and resequencing segment held the highest market share of 75.9% in 2022. This segment is expected to witness growth in demand after the growth of whole genome sequencing, as the availability of a large amount of whole genome data will be required to be analyzed at specific gene locations and isolated genetic expressions. There are many companies in the NGS market offering targeted sequencing services. Thus, this segment is expected to grow in tandem with the WGS segment throughout the forecast period.
Illumina offers targeted resequencing with its gene panel and array finder, whereas Pacific Biosciences of California’s Sequel System with its SMRT technique allows targeted sequencing and accurate detection of variants. Targeted sequencing panels are expected to remain the workhorse for cancer molecular diagnostics and are projected to become the routine part of the heme malignancies and solid tumors.
Workflow Insights
The sequencing segment held the highest market share of 55.7% in 2022. NGS sequencing is the most important phase of the workflow and consequently accounts for the largest share of the market. These systems can provide an accurate amount of liquid, which is important in NGS. Moreover, functions such as changing tubes and microtiter plates are also carried out by the system, which helps streamline workflow. The advantage of using a robotic liquid handling system is that it enables researchers to focus on analyzing the data rather than managing the process.
For instance, Illumina's BaseSpace Suite aids in the analysis of sequencing data and the production of findings in a short amount of time. To expand its data analytic capabilities, the company has also purchased DRAGEN Bio-IT Platform (DRAGEN) and Edico Genome. Furthermore, Genomatix and DNAnexus, provide cloud-based solutions for the interpretation and management of enormous volumes of sequencing data.
End-use Insights
The academic research segment held the highest market share of 53.9% in 2022. The application of NGS solutions in research projects that are carried out in the universities and research centers can be attributed to the largest share of this segment in the market. Furthermore, scholarships offered for Ph.D. projects in NGS are anticipated to drive demand for NGS products and services, thereby resulting in lucrative growth over the forecast period. Provision of on-site bioinformatics courses that include workshops on the practical implementation of NGS sequencing and data analysis are also expected to boost revenue generated through the academic research segment in the coming years.
Owing to the use of NGS in cancer research and, more specifically, in the discovery of new cancer-related genes, studying tumor heterogeneity, and identification of alterations that are contributive to tumorigenesis the segment is expected to witness significant growth through to 2028. In addition, the availability of clinical research solutions through market entities such as Illumina, Thermo Fisher Scientific Corporation, and Agilent Technologies for target enrichment and detection is anticipated to provide this segment with high growth opportunities over the forecast period.
Regional Insights
North America dominated the NGS market and accounted for the largest revenue share of 50.2% in 2022. The regional market is driven by the presence of multiple clinical laboratories that employ NGS to provide genetic testing services. Furthermore, due to the presence of high R&D investment, and the availability of a technologically advanced healthcare research framework, the development of WGS in the region is also expected to serve as a critical factor for the growth of the market in North America throughout the forecast period.
In Asia Pacific, the market is estimated to grow fast over the forecast period owing to the presence of significant developments by China and Japan for technological integration of NGS methodologies, and the development of healthcare, R&D, and clinical development frameworks of emerging economies such as India and Australia have poised the Asia Pacific NGS market to witness lucrative opportunities of growth throughout the forecast period.
Some of the prominent players in the Next-generation Sequencing Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Next-generation Sequencing market.
By Geography
Key Benefits for Stakeholders
Chapter 1. Introduction
1.1 Information Procurement
1.1.1 Purchased database
1.1.2 nova one advisor’s internal database
1.1.3 Secondary sources
1.1.4 Third Party Perspective
1.1.5 Primary Research
1.2 Information or Data Analysis
1.3 Market Formulation & Validation
1.4 Region Wise Market Calculation
1.4.1 Region wise market: Base estimates
1.4.2 Global market: CAGR calculation
1.4.3 Region based segment share calculation
Chapter 2 Executive Summary
2.1 Market Outlook
Chapter 3 Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1 Parent market outlook
3.1.2 Related/ancillary market outlook
3.2 Cost Structure Analysis
3.3 User Perspective Analysis
3.3.1 Consumer behavior analysis
3.3.2 Market influencer analysis
3.4 Procedure Cost Analysis
3.5 List of Key End Users
3.6 Technology Overview
3.6.1 Technology timeline
3.7 Impact of COVID-19 Pandemic
3.7.1 Impact on the supply chain
3.7.2 Association of COVID-19 with next-generation sequencing
3.8 Market Segmentation & Scope
3.8.1 Market driver analysis
3.8.1.1 Exponentially decreasing costs for genetic sequencing
3.8.1.2 Development of companion diagnostics and personalized medicine
3.8.1.3 Rise in competition amongst prominent market entities
3.8.1.4 Rising clinical opportunity for NGS technology
3.8.1.5 Technological advancements in cloud computing and data integration
3.8.1.6 Growing healthcare expenditure supporting development of effective PM diagnostic & therapeutic procedures for cancer
3.8.1.7 Increasing prevalence of cancer
3.8.2 Market restraint analysis
3.8.2.1 Lack of computational efficiency for data management
3.8.2.2 Non-value based NGS reimbursement policy and regulation status
3.8.2.3 Challenges associated with NGS implementation
3.9 Penetration & Growth Prospect Mapping for Applications, 2019
3.10 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.11 NGS Platform Penetration Mapping, 2019
3.11.1 Next generation sequencing reimbursement environment
3.11.2 Gap fill approach for reimbursement of NGS tests
3.11.3 Role of the commercial payers
3.11.3.1 Payer perspectives for developing coverage policy for Next-Generation Tumor Sequencing Panels (NGTS)
3.11.3.2 Role of diagnostic laboratories and pathology centers
3.11.4 North America
3.11.4.1 U.S.
3.11.4.2 Canada
3.11.5 Europe
3.11.5.1 UK
3.11.5.2 Germany
3.11.5.3 Spain
3.11.6 Asia Pacific
3.11.7 Latin America
3.11.8 Middle East Africa
3.11.9 Next-Generation Sequencing Market: Regional Market Share, 2021
3.12 Next-Generation Sequencing Regulatory and Political Environment
3.12.1 Next-Generation Sequencing North America Regulatory and Political Landscape Analysis, 2021
3.12.1.1 U.S.
3.12.1.2 Canada
3.12.2 Next-Generation Sequencing Europe Regulatory and Political Landscape Analysis, 2021
3.12.2.1 UK
3.12.2.2 Germany
3.12.2.3 France
3.12.2.4 Spain
3.12.3 Next-Generation Sequencing Asia Pacific Regulatory and Political Landscape Analysis, 2021
3.12.3.1 Japan
3.12.3.2 China
3.12.4 Next-Generation Sequencing Latin America Regulatory and Political Landscape Analysis, 2021
3.12.4.1 Brazil
3.12.4.2 Mexico
3.12.4.3 Argentina
3.12.5 Next-Generation Sequencing Middle East & Africa Regulatory and Political Landscape Analysis, 2021
3.12.5.1 South Africa
3.12.5.2 Qatar
3.12.5.3 Kuwait
3.12.5.4 UAE
3.12.5.5 Saudi Arabia
3.13 Next-Generation Sequencing - SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.14 Industry Analysis - Porter’s
3.14.1 Major deals & strategic alliances analysis
3.14.1.1 Joint ventures
3.14.1.2 Mergers & acquisitions
3.14.1.3 Licensing & partnership
3.14.2 Technology collaborations
3.15 Market Entry Strategies
3.16 Case Studies
3.16.1 Impact of NGS on Treatment Selection in acute myeloid leukemia (AML)
Chapter 4 Competitive Analysis
4.1 Recent Developments & Impact Analysis, by Key Market Participants
4.2 Company Categorization
4.3 Public Companies
4.3.1 List of key distributors and channel partners
4.3.1.1 Service providers, manufacturers, & suppliers of products
4.3.1.2 Key distributors and channel partners of Illumina
4.3.1.2.1 Americas (North, South, & Central America)
4.3.1.2.2 Europe
4.3.1.2.3 Asia/Central Pacific
4.3.1.2.4 Middle East & Africa
4.3.1.3 Service providers of ThermoFisher
4.3.1.3.1 North America
4.3.1.3.2 EMEA
4.3.1.3.3 Asia Pacific
4.3.2 Key customers
4.3.3 Key company market share analysis, 2019
4.3.3.1 Company size
4.3.3.2 Geographical presence
4.3.3.3 Product portfolio
4.3.4 Competitive dashboard analysis
4.3.5 Market differentiators
4.3.6 Private companies
4.3.6.1 List of emerging players
4.3.6.2 Funding outlook
4.3.6.3 Regional network map
4.3.6.4 Company market position analysis, 2019
4.3.6.5 List of suppliers
Chapter 5 NGS Application Estimates & Trend Analysis
5.1 Next-Generation Sequencing Market: Application Movement Analysis
5.2 Oncology
5.2.1 Global oncology market, 2018 - 2032
5.2.2 Diagnostics and screening
5.2.2.1 Diagnostics and screening market, 2018 - 2032
5.2.2.2 Oncology screening
5.2.2.2.1 Oncology screening market, 2018 - 2032
5.2.2.2.2 Sporadic cancer screening market, 2018 - 2032
5.2.2.2.3 Inherited cancer screening market, 2018 - 2032
5.2.2.3 Companion diagnostics
5.2.2.3.1 Companion diagnostics market, 2018 - 2032
5.2.2.4 Other diagnostics
5.2.2.4.1 Other diagnostics market, 2018 - 2032
5.2.3 Research studies
5.2.3.1 Research studies market, 2018 - 2032
5.3 Clinical Investigation
5.3.1 Global clinical investigation market, 2018 - 2032
5.3.2 Infectious diseases
5.3.2.1 Global infectious diseases market, 2018 - 2032
5.3.3 Inherited diseases
5.3.3.1 Global inherited diseases market, 2018 - 2032
5.3.4 Idiopathic diseases
5.3.4.1 Global idiopathic diseases market, 2018 - 2032
5.3.5 Non-communicable/other diseases
5.3.5.1 Global non-communicable/other diseases market, 2018 - 2032
5.4 Reproductive Health
5.4.1 Global reproductive health market, 2018 - 2032
5.4.2 NIPT
5.4.2.1 Global NIPT market, 2018 - 2032
5.4.2.2 Aneuploidy
5.4.2.2.1 Global aneuploidy market, 2018 - 2032
5.4.2.3 Microdeletions
5.4.2.3.1 Global microdeletions market, 2018 - 2032
5.4.3 PGT
5.4.3.1 Global NGS PGT market, 2018 - 2032
5.4.4 New-born/genetic screening
5.4.4.1 Global newborn/genetic screening market, 2018 - 2032
5.4.5 Single gene analysis
5.4.5.1 Single gene analysis market, 2018 - 2032
5.5 HLA Typing/Immune System Monitoring
5.5.1 Global HLA typing/immune system monitoring market, 2018 - 2032
5.6 Metagenomics, Epidemiology & Drug Development
5.6.1 Global metagenomics, epidemiology & drug development market, 2018 - 2032
5.7 Agrigenomics & Forensics
5.7.1 Global agrigenomics & forensics market, 2018 - 2032
5.8 Consumer Genomics
5.8.1 Global consumer genomics market, 2018 - 2032
Chapter 6 NGS Technology Estimates & Trend Analysis
6.1 Next-Generation Sequencing Market: Technology Movement Analysis
6.2 Whole Genome Sequencing
6.2.1 Global whole genome sequencing market, 2018 - 2032
6.3 Whole Exome Sequencing
6.3.1 Global whole exome sequencing market, 2018 - 2032
6.4 Targeted Sequencing & Resequencing
6.4.1 Global targeted sequencing & resequencing market, 2018 - 2032
6.4.2 DNA based targeted sequencing & resequencing
6.4.2.1 Global DNA based targeted sequencing & resequencing market, 2018 - 2032
6.4.3 RNA-based targeted sequencing & resequencing
6.4.3.1 Global RNA based targeted sequencing & resequencing market, 2018 - 2032
Chapter 7 NGS Product Estimates & Trend Analysis
7.1 Next-Generation Sequencing Market: Product Movement Analysis
7.2 Platforms
7.2.1 Global platforms market, 2018 - 2032
7.2.2 Sequencing Platforms
7.2.2.1 Global sequencing platforms market, 2018 - 2032
7.2.3 Data Analysis Platforms
7.2.3.1 Global data analysis platforms market, 2018 - 2032
7.3 Consumables
7.3.1 Global consumables market, 2018 - 2032
7.3.2 Sample Preparation
7.3.2.1 Global sample preparation market, 2018 - 2032
7.3.3 Target Enrichment
7.3.3.1 Global target enrichment consumables market, 2018 - 2032
7.3.4 Others
7.3.4.1 Global other consumables market, 2018 - 2032
Chapter 8 NGS Workflow Estimates & Trend Analysis
8.1 Next-Generation Sequencing Market: Workflow Movement Analysis
8.2 Pre-Sequencing
8.2.1 Global pre-sequencing market, 2018 - 2032
8.2.2 NGS library preparation kits
8.2.2.1 Global NGS library preparation kits market, 2018 - 2032
8.2.3 NGS semi-automated library preparation
8.2.3.1 Global NGS semi-automated library preparation market, 2018 - 2032
8.2.4 NGS automated library preparation
8.2.4.1 Global NGS automated library preparation market, 2018 - 2032
8.2.5 Clonal amplification
8.2.5.1 Global clonal amplification market, 2018 - 2032
8.3 Sequencing
8.3.1 Global sequencing market, 2018 - 2032
8.4 Data Analysis
8.4.1 Global data analysis market, 2018 - 2032
8.4.2 NGS primary data analysis
8.4.2.1 Global NGS primary data analysis market, 2018 - 2032
8.4.3 NGS secondary data analysis
8.4.3.1 Global NGS secondary data analysis market, 2018 - 2032
8.4.4 NGS tertiary data analysis
8.4.4.1 Global NGS tertiary data analysis services market, 2018 - 2032
Chapter 9 NGS End-use Estimates & Trend Analysis
9.1 Next-Generation Sequencing Market: End-Use Movement Analysis
9.2 Academic Research
9.2.1 Global academic research market, 2018 - 2032
9.3 Clinical Research
9.3.1 Global clinical research market, 2018 - 2032
9.4 Hospitals & Clinics
9.4.1 Global hospitals & clinics market2018 - 2032
9.5 Pharma & Biotech Entities
9.5.1 Global pharma & biotech entities market, 2018 - 2032
9.6 Other Users
9.6.1 Global other users market, 2018 - 2032
Chapter 10 NGS Regional Estimates & Trend Analysis, by Product & Service Type, Application, Technology, Workflow, & End-use
10.1 Next generation sequencing market share by region, 2019 & 2027
10.2 Regional Market Share and Leading Players, 2019
10.3 North America
10.3.1 North America next-generation sequencing market, 2018 - 2032
10.3.2 U.S.
10.3.2.1 U.S. next-generation sequencing market, 2018 - 2032
10.3.3 Canada
10.3.3.1 Canada next-generation sequencing market, 2018 - 2032
10.4 Europe
10.4.1 Europe next-generation sequencing market, 2018 - 2032
10.4.2 Germany
10.4.2.1 Germany next-generation sequencing market, 2018 - 2032
10.4.3 UK
10.4.3.1 UK next-generation sequencing market, 2018 - 2032
10.4.4 France
10.4.4.1 France next-generation sequencing market, 2018 - 2032
10.4.5 Spain
10.4.5.1 Spain next-generation sequencing market, 2018 - 2032
10.4.6 Italy
10.4.6.1 Italy next-generation sequencing market, 2018 - 2032
10.5 Asia Pacific
10.5.1 Asia Pacific next-generation sequencing market, 2018 - 2032
10.5.2 Japan
10.5.2.1 Japan next-generation sequencing market, 2018 - 2032
10.5.3 China
10.5.3.1 China next-generation sequencing market, 2018 - 2032
10.5.4 India
10.5.4.1 India next-generation sequencing market, 2018 - 2032
10.5.5 Australia
10.5.5.1 Australia next-generation sequencing market, 2018 - 2032
10.5.6 South Korea
10.5.6.1 South Korea next-generation sequencing market, 2018 - 2032
10.6 Latin America
10.6.1 Latin America next-generation sequencing market, 2018 - 2032
10.6.2 Brazil
10.6.2.1 Brazil next-generation sequencing market, 2018 - 2032
10.6.3 Mexico
10.6.3.1 Mexico next-generation sequencing market, 2018 - 2032
10.7 Middle East & Africa
10.7.1 Middle East & Africa next-generation sequencing market, 2018 - 2032
10.7.2 South Africa
10.7.2.1 South Africa next-generation sequencing market, 2018 - 2032
10.7.3 Saudi Arabia
10.7.3.1 Saudi Arabia next-generation sequencing market, 2018 - 2032
Chapter 11 Competitive Landscape
11.1. Strategy Framework
11.2. Market Participation Categorization
11.3. Next-Generation Sequencing Vendor’s Landscape
11.4. Champions
11.5. Innovators
11.6. Emerging players
11.7. Market pillars
11.8. Company Profiles
11.8.1 Illumina, Inc.
11.8.1.1 Company overview
11.8.1.2 Financial performance
11.8.1.3 Product benchmarking
11.8.1.4 Strategic initiatives
11.8.2 F. Hoffmann-La Roche Ltd.
11.8.2.1 Company overview
11.8.2.2 Financial performance
11.8.2.3 Product benchmarking
11.8.2.4 Strategic initiatives
11.8.3 Agilent Technologies, Inc.
11.8.3.1 Company overview
11.8.3.2 Financial performance
11.8.3.3 Product benchmarking
11.8.3.4 Strategic initiatives
11.8.4 PierianDx
11.8.4.1 Company overview
11.8.5 Tute Genomics
11.8.5.1 Company overview
11.8.6 Knome, Inc.
11.8.6.1 Company overview
11.8.6.2 Financial performance
11.8.6.3 Product benchmarking
11.8.6.4 Strategic initiatives
11.8.7 Intrexon Bioinformatics Germany GmbH
11.8.7.1 Company overview
11.8.7.2 Financial performance
11.8.7.3 Product benchmarking
11.8.7.4 Strategic initiatives
11.8.8 Eurofins Scientific
11.8.8.1 Company overview
11.8.8.2 Eurofins GATC Biotech GmbH
11.8.8.2.1 Company overview
11.8.8.3 Financial performance
11.8.8.3.1 Financial performance: Eurofins GATC Biotech GmbH
11.8.8.4 Product benchmarking
11.8.8.5 Strategic initiatives
11.8.9 Oxford Nanopore Technologies
11.8.9.1 Company overview
11.8.9.2 Financial performance
11.8.9.3 Product benchmarking
11.8.9.4 Strategic initiatives
11.8.10 Macrogen, Inc.
11.8.10.1 Company overview
11.8.10.2 Financial performance
11.8.10.3 Product benchmarking
11.8.10.4 Strategic initiatives
11.8.11 DNASTAR, Inc.
11.8.11.1 Company overview
11.8.11.2 Financial Performance
11.8.11.3 Product benchmarking
11.8.11.4 Strategic initiatives
11.8.12 Thermo Fisher Scientific, Inc.
11.8.12.1 Company overview
11.8.12.1.1 Life Technologies Corp.
11.8.12.2 Financial performance
11.8.12.3 Product benchmarking
11.8.12.4 Strategic initiatives
11.8.13 Biomatters Ltd.
11.8.13.1 Company overview
11.8.13.2 Financial performance
11.8.13.3 Product benchmarking
11.8.13.4 Strategic initiatives
11.8.14 QIAGEN
11.8.14.1 Company overview
11.8.15 Ingenuity
11.8.16 CLC Bio
11.8.16.2 Financial performance
11.8.16.3 Product benchmarking
11.8.16.4 Strategic initiatives
11.8.17 BGI
11.8.17.1 Company overview
11.8.17.1.1 Complete Genomics Incorporated
11.8.17.2 Financial performance
11.8.17.3 Product benchmarking
11.8.17.4 Strategic initiatives
11.8.18 Perkin Elmer, Inc.
11.8.18.1 Company overview
11.8.18.2 PERKINELMER GENOMICS
11.8.18.3 Financial performance
11.8.18.4 Product benchmarking
11.8.18.5 Strategic initiatives
11.8.19 Pacific Biosciences of California, Inc.
11.8.19.1 Company overview
11.8.19.2 Financial performance
11.8.19.3 Product benchmarking
11.8.19.4 Strategic initiatives
11.8.20 Partek Incorporated
11.8.20.1 Company overview
11.8.20.2 Financial performance
11.8.20.3 Product benchmarking
11.8.20.4 Strategic initiatives
11.8.21 Bio-Rad Laboratories, Inc.
11.8.21.1 Company overview
11.8.22 GnuBio
11.8.22.1 Company overview
11.8.22.2 Financial performance
11.8.22.3 Product benchmarking
11.8.22.4 Strategic initiatives
11.8.23 Myriad Genetics, Inc.
11.8.23.1 Company overview
11.8.23.2 Financial performance
11.8.23.3 Product benchmarking
11.8.22.4 Strategic initiatives
11.8.24 Hologic, Inc. (Gen-Probe Incorporated)
11.8.24.1 Company overview
11.8.24.2 Financial performance
11.8.24.3 Product benchmarking
11.8.24.4 Strategic initiatives
11.8.25 Horizon Discovery Group plc
11.8.25.1 Company overview
11.8.25.2 Financial performance
11.8.25.3 Product benchmarking
11.8.25.4 Strategic initiatives
11.8.26 LGC Limited
11.8.26.1 Company overview
11.8.27 SeraCare
11.8.27.1 Company overview
11.8.27.2 Financial performance (LGC Limited)
11.8.27.3 Product benchmarking
11.8.27.4 Strategic initiatives
11.8.28 Vela Diagnostics
11.8.28.1 Company overview
11.8.28.2 Financial performance
11.8.28.3 Product benchmarking
11.8.28.4 Strategic initiatives
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers